AvKARE Recalls Losartan Potassium Tablets Due to Impurity
AvKARE Inc. is recalling Losartan Potassium Tablets 25 mg because FDA testing found an impurity above acceptable levels.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the presence of a nitrosamine impurity (NMBA) above acceptable limits represents a significant health risk, aligning with the 'Severe' criteria for significant injury/property-damage reports or high-risk contamination.
Plain-English summary
AvKARE Inc. is recalling Losartan Potassium Tablets USP 25 mg (NDC 50268-516-15). The recall involves 846 cartons containing 42,300 tablets, distributed nationwide. The specific lot number is 19554, with an expiration date of 4/30/2019.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. FDA laboratory testing confirmed the presence of the impurity N-Methylnitrosobutyric acid (NMBA) in the finished product at levels exceeding the interim acceptable daily intake limit of 0.96 parts per million.
Consumers and healthcare providers should check their inventory for this specific lot and expiration date. If found, the product should be discontinued and returned to the supplier or disposed of according to local regulations.
The recalled product
- Product
- Losartan Potassium Tablets USP 25 mg 50 tablets (5x10) Unit Dose Rx Only NDC 50268-516-15 Manufactured for: AvKARE Inc. Pulaski, TN 38478
- Manufacturer
- AVKARE Inc.
- Category
- Drug — Prescription Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 19554 Exp. 4/30/2019
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by AVKARE Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · AVKARE Inc.
See all →- ModerateLamotrigine Tablets Recalled for Label Strength Error
FDA (Drugs) · 2022-08-17
- ModeratePhytonadione Tablets 5 mg Recalled Due to Failed Impurities Specification
FDA (Drugs) · 2021-06-23
- CriticalAvKare Recalls Trazodone Hydrochloride Tablets Due to Sildenafil Packaging Mix-Up
FDA (Drugs) · 2020-12-23
- ModerateAvKARE Recalls Sildenafil Tablets Due to Packaging Mix-Up with Trazodone
FDA (Drugs) · 2020-12-23
- ModerateAvKARE Recalls Mesalamine Tablets for Failed Dissolution Specifications
FDA (Drugs) · 2020-11-18
Same hazard · impurity
See all →- ModerateAjanta Pharma Recalls Fluphenazine Hydrochloride Tablets Due to Impurity Failure
FDA (Drugs) · 2026-09-16
- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
Similar recalls
- SevereAvKARE Recalls Losartan Potassium Tablets Due to Impurity
FDA (Drugs) · 2019-03-27
- SevereAvKARE Recalls Losartan Potassium and Hydrochlorothiazide Tablets Due to Impurity
FDA (Drugs) · 2019-03-27
- SevereLosartan Potassium Tablets Recalled Due to Impurity Presence
FDA (Drugs) · 2019-05-29
- SevereLosartan Potassium Tablets Recalled Due to Impurity Detection
FDA (Drugs) · 2019-07-17
- SevereLosartan Potassium Tablets Recalled Due to Nitrosamine Impurity
FDA (Drugs) · 2019-07-17
- SevereAvet Pharmaceuticals Recalls Losartan Potassium Tablets Due to Impurity
FDA (Drugs) · 2020-04-15